REBECCA, REsearch on BrEast Cancer induced chronic conditions supported by Causal Analysis of multi-source data, aims to tap into the potential of Real-World Data to support clinical research and to improve post-treatment in breast cancer.
REBECCA kicked off in April 2021 and is set to last until March 2025. The project consortium, 12 partners from 7 European countries, is made up of clinical and technological universities, industry leaders, public health experts, and patient associations. The project budget is 5.2 million EUR, provided under the European Union’s Horizon 2020 research and innovation programme.
Objectives and methodology
REBECCA will combine clinical data with data obtained from multiple wearable, online behaviour and registry data to study the complex array of chronic comorbidities developed during breast cancer recovery. The data will be deployed within 7 clinical studies in 3 countries, Norway, Spain and Sweden, involving over 650 individuals, and it will help shape future guidelines and practices for post-cancer treatment. Best practices resulting from the studies will be disseminated to researchers, public health and regulatory bodies throughout Europe.
To realise its Research and Innovation mission, over the course of 4 years REBECCA will pursue a set of methodology, technology, validation, and impact objectives with the principal goal of improving clinical research on complex chronic conditions and improving the healthcare outcomes for patients who have undergone or are still in primary cancer treatment.
EHMA’s role in the project
EHMA is a leader of Work Package 8 on Dissemination and communication. EHMA will develop and implement a communication strategy, aiming to reach out to the different target audience segments of REBECCA and raise awareness about the project and its results. EHMA will also build and engage a network of public health stakeholders to promote the value of using Real-World data in research and clinical practice in the breast cancer domain.